Repositioning Candidate Details
Candidate ID: | R1598 |
Source ID: | DB16448 |
Source Type: | investigational |
Compound Type: | biotech |
Compound Name: | CD24Fc |
Synonyms: | Human CD24 and human IgG Fc Fusion Protein |
Molecular Formula: | -- |
SMILES: | -- |
DrugBank Description: | CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients. |
CAS Number: | -- |
Molecular Weight: | |
DrugBank Indication: | -- |
DrugBank Pharmacology: | -- |
DrugBank MoA: | CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients. It has protective abilities against inflammatory mediators and potential to reduce lung pathology associated with pneumonia. The specific mechanisms by which CD24Fc works is currently unknown. |
Targets: | -- |
Inclusion Criteria: | Therapeutic strategy associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Diseases ID | DO ID | Disease Name | Definition | Class | |
---|---|---|---|---|---|
I01 | 552 | Pneumonia | A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. http://en.wikipedia.org/wiki/Pneumonia | disease of anatomical entity/respiratory system disease/ lower respiratory tract disease/lung disease | Details |